The potential of serum elabela levels as a marker of diabetic retinopathy: results from a pilot cross-sectional study
- PMID: 39802191
- PMCID: PMC11724653
- DOI: 10.7717/peerj.18841
The potential of serum elabela levels as a marker of diabetic retinopathy: results from a pilot cross-sectional study
Abstract
Background: The aim of this study is to examine the relationship between elabela (ELA), a recently identified peptide also known as Toddler and Apela, and diabetic retinopathy (DR). ELA, produced in various tissues, acts as a natural ligand for the apelin receptor (APJ). Upon reviewing the existing literature, only one study was found investigating ELA, one of the APJ ligands, in the pathogenesis of DR.
Methods: In our study the patient group comprising individuals diagnosed with type 2 diabetes mellitus (DM), categorized into three subgroups based on detailed fundus examination: those without DR (non-DR) (n = 20), non-proliferative DR (NPDR) (n = 20), and proliferative DR (PDR) (n = 20). A control group (n = 20) consisted of individuals without DM. Blood samples were collected during outpatient clinic admission to measure serum ELA levels, which were determined using a commercial ELISA kit.
Results: The age, sex, and body mass index of the between groups were similar (p = 0.905, 0.985 and 0.241, respectively). The HbA1c levels of the between DM subgroups were similar (p = 0.199). Serum ELA levels were 217.19 ± 97.54 pg/mL in the non-DR group, 221.76 ± 93.12 pg/mL in the NPDR group, 302.35 ± 146.17 pg/mL in the PDR group and 216.49 ± 58.85 pg/mL in the control group. While ELA levels were higher in DM patients compared to the control group, this elevation did not reach statistical significance. Further analysis dividing DM patients into subgroups (non-DR, NPDR, and PDR) revealed higher ELA levels in the PDR group compared to the other subgroups, but this increase was not statistically significant.
Conclusion: Despite the absence of a significant difference in our study, the identification of elevated ELA levels in the PDR group offers valuable insights for future investigations exploring the association between DR and ELA.
Keywords: Apelin; Apelin receptor; Diabetic retinopathy; Elabela.
© 2025 Seyithanoğlu et al.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures
Similar articles
-
Serum cortisol is a biomolecular biomarker for severity of diabetic retinopathy.Mol Vis. 2021 Jul 3;27:429-437. eCollection 2021. Mol Vis. 2021. PMID: 34267498 Free PMC article.
-
Serum Elabela/Toddler Levels Are Associated with Albuminuria in Patients with Type 2 Diabetes.Cell Physiol Biochem. 2018;48(3):1347-1354. doi: 10.1159/000492093. Epub 2018 Jul 26. Cell Physiol Biochem. 2018. PMID: 30048993
-
Diagnostic and prognostic role of serum miR-20b, miR-17-3p, HOTAIR, and MALAT1 in diabetic retinopathy.IUBMB Life. 2019 Mar;71(3):310-320. doi: 10.1002/iub.1970. Epub 2018 Nov 23. IUBMB Life. 2019. PMID: 30468285
-
Prognostic factors for the development and progression of proliferative diabetic retinopathy in people with diabetic retinopathy.Cochrane Database Syst Rev. 2023 Feb 22;2(2):CD013775. doi: 10.1002/14651858.CD013775.pub2. Cochrane Database Syst Rev. 2023. PMID: 36815723 Free PMC article. Review.
-
Serum Vascular Endothelial Growth Factor Levels Correlate with Severity of Retinopathy in Diabetic Patients: A Systematic Review and Meta-Analysis.Dis Markers. 2019 Mar 24;2019:9401628. doi: 10.1155/2019/9401628. eCollection 2019. Dis Markers. 2019. PMID: 31019585 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical